KEAP1/NFE2L2通路特征优于KEAP1/NFE2L2突变状态并揭示非小细胞肺癌中的替代性通路激活突变
研究基于971例非小细胞肺癌样本训练46基因表达特征K1N2评分以预测KEAP1/NFE2L2突变,并在348例院内样本中验证。验证集AUC为89.5、敏感性90.2%,评分预测生存优于突变状态(评分P=0.047;突变P=0.215),并在野生型样本中检出SMARCA4/BRG1与CUL3突变为模拟性激活因素。
要点
- 46基因K1N2评分可稳健预测KEAP1/NFE2L2突变,验证集AUC 89.5、敏感性90.2%。
- 预测患者生存时K1N2评分优于KEAP1/NFE2L2突变状态(评分P=0.047;突变P=0.215)。
- K1N2评分阳性而KEAP1/NFE2L2野生型样本中,SMARCA4/BRG1与CUL3突变被鉴定为模拟激活因素。
核心结论
- K1N2评分通过稳健检出KEAP1/NFE2L2突变病例并发现替代性基因组激活因素来识别KEAP1/NFE2L2激活型非小细胞肺癌。
- K1N2评分是筛选KEAP1/NFE2L2通路组成性激活患者的一种潜在手段。
研究设计与样本
- 研究使用共971例非小细胞肺癌样本训练预测KEAP1/NFE2L2突变的表达特征K1N2评分。
- 采用NanoString表达面板分析348例院内非小细胞肺癌样本进行验证。
主要发现
- 46基因K1N2评分在验证集中稳健预测KEAP1/NFE2L2突变,不受组织学类型和突变类型影响,曲线下面积为89.5、敏感性为90.2%。
- 上述结果提示约90%的KEAP1/NFE2L2突变为通路激活型。
- 预测患者生存时K1N2评分优于KEAP1/NFE2L2突变状态(评分P=0.047;突变P=0.215)。
- 在K1N2评分阳性但KEAP1/NFE2L2野生型样本中,富集检验鉴定SMARCA4/BRG1和CUL3突变为KEAP1/NFE2L2突变的模拟因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Activation of the antioxidant KEAP1/NFE2L2 (NRF2) pathway leads to increased glutamine dependence and an aggressive phenotype in NSCLC. Because this pathway has been explored as a clinical target, we developed a transcriptomic signature for identifying KEAP1/NFE2L2-activated tumors. METHODS: A total of 971 NSCLC samples were used to train an expression signature (K1N2-score) to predict KEAP1/NFE2L2 mutations. There were 348 in-house NSCLCs that were analyzed using a NanoString expression panel for validation. RESULTS: The 46-gene K1N2 score robustly predicted KEAP1/NFE2L2 mutations in the validation set irrespective of histology and mutation (area under the curve: 89.5, sensitivity: 90.2%), suggesting that approximately 90% of KEAP1/NFE2L2 mutations are pathway-activating. The K1N2-score outperformed KEAP1/NFE2L2 mutational status when predicting patient survival (score p = 0.047; mutation p = 0.215). In K1N2 score-positive but KEAP1/NFE2L2 wild-type samples, enrichment testing identified SMARCA4/BRG1 and CUL3 mutations as mimics of KEAP1/NFE2L2 mutations. CONCLUSIONS: The K1N2-score identified KEAP1/NFE2L2-activated NSCLC by robustly detecting KEAP1/NFE2L2mut cases and discovering alternative genomic activators. It is a potential means for selecting patients with a constitutively active KEAP1/NFE2L2 pathway.
引用
- Arolt C, Dugan M, Wild R, et al. KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC. J Thorac Oncol. 2023. PMID: 37473958. doi:10.1016/j.jtho.2023.07.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。